Antitumor Activity of Lanreotide Autogel 120 mg in Enteropancreatic Neuroendocrine Tumour (NET) Patients: The Clarinet Open-Label Extension Study
M Pavel, M Caplin, JB Ćwikła, A Phan, M Raderer, E Sedláčková, G Cadiot, E Wolin, J Capdevila, L Wall, G Rindi, A Langley, E Gomez-Panzani, P Ruszniewski · Zeitschrift für Gastroenterologie · 2015 · Heft 08
Bibliografische Angaben
Zusammenfassung
Introduction: CLARINET core study data has demonstrated the efficacy and safety/tolerability of lanreotide as an antitumor treatment in patients with metastatic enteropancreatic NETs. Here, we report updated PFS data and safety findings from the CLARINET open-label extension (OLE; NCT00842348). Methods: In the core study, patients with metastatic well/moderately differentiated non-functioning enteropancreatic NETs, Ki-67 Ki-67 < 10%, no prior medical therapy in last 6 months were randomized to lanreotide Autogel 120 mg (n = 101) or placebo (n = 103) for 96 weeks or until progressive disease (PD)/death. In the OL…
